Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.49 AUD | -1.01% | -2.00% | -40.96% |
05-21 | Transcript : Aroa Biosurgery Limited, 2024 Earnings Call, May 21, 2024 | |
05-21 | Aroa Biosurgery Limited Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-40.96% | 113M | - | ||
+11.74% | 28.61B | B+ | ||
-32.33% | 3.02B | B- | ||
+32.96% | 2.61B | B | ||
-17.26% | 2.49B | C+ | ||
+4.75% | 2.19B | - | A- | |
-6.23% | 1.98B | - | ||
+32.22% | 2.03B | B | ||
+27.35% | 1.33B | B | ||
+31.89% | 1.33B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ARX Stock
- Ratings Aroa Biosurgery Limited